The results are promising and favor the LAMA/LABA inhalers, especially in the longer duration trials. Furthermore, there is a clearer picture emerging as to the subgroup of COPD patients who may be able to successfully switch from their current ICS/LABA therapy to these new...
The results are promising and favor the LAMA/LABA inhalers, especially in the longer duration trials. Furthermore, there is a clearer picture emerging as to the subgroup of COPD patients who may be able to successfully switch from their current ICS/LABA therapy to these new LAMA/LABA inhaler...
With multiple add-on therapies available for the management of asthma, there have been several systematic reviews published that evaluate the efficacy and safety of add-on therapies compared with either placebo or another add-on therapy14,15,16,17,19,20. However, none compare LABA, LTRA and L...
GFF MDI (Bevespi Aerosphere®) is a fixed-dose combination (FDC) of GP (14.4 μg) and the LABA formoterol fumarate dihydrate (FF; 10 μg), delivered by a metered dose inhaler (MDI) using innovative co-suspension delivery technology [[17], [18], [19]]. GFF MDI is the first...
Inhaled bronchodilators including long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) play a central role in the treatment of stable chronic obstructive pulmonary disease (COPD). However, it is still unclear whether LABA or LAMA should be used for the initial treatment. ...
Patients were excluded if, during the 12-month baseline period, they had evidence of lung cancer, or had prescription claims for any ICS-or LABA-con- taining therapy but did not self-report a current LAMA prescription. Eligible patients identified from the claims were subsequently recruited by ...
Fenwick E, Martin A, Schroeder M, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK.ERJ Open Res. 2021;7(1):00480–2020. PubMedGoogle Scholar Mauskopf J, Earnshaw SR, Brogan A, et al. Budget-impact analysis of health care interventions. 1st ed....
InhalersLABALAMAPharmacotherapyInhaled fixed-dose combinations (FDCs) of a long-acting 尾-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) have become the cornerstone for the maintenance treatment of symptomatic COPD patients. In this regard, global COPD treatment guidelines have ...